212 related articles for article (PubMed ID: 31162796)
21. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
[TBL] [Abstract][Full Text] [Related]
22. Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer.
Fujimura T; Takahashi S; Urano T; Takayama K; Sugihara T; Obinata D; Yamada Y; Kumagai J; Kume H; Ouchi Y; Inoue S; Homma Y
Clin Cancer Res; 2014 Sep; 20(17):4625-35. PubMed ID: 24987058
[TBL] [Abstract][Full Text] [Related]
23. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
24. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.
Roudier MP; True LD; Higano CS; Vesselle H; Ellis W; Lange P; Vessella RL
Hum Pathol; 2003 Jul; 34(7):646-53. PubMed ID: 12874759
[TBL] [Abstract][Full Text] [Related]
26. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.
Sawada Y; Kikugawa T; Iio H; Sakakibara I; Yoshida S; Ikedo A; Yanagihara Y; Saeki N; Győrffy B; Kishida T; Okubo Y; Nakamura Y; Miyagi Y; Saika T; Imai Y
Int J Cancer; 2020 Mar; 146(5):1369-1382. PubMed ID: 31276604
[TBL] [Abstract][Full Text] [Related]
27. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
28. NANOG as prognostic factor of prostate cancer course.
Zadvornyi TV; Lukianova NY; Borikun TV; Vitruk YV; Stakhovsky EO; Chekhun VF
Exp Oncol; 2020 Jun; 42(2):94-100. PubMed ID: 32602285
[TBL] [Abstract][Full Text] [Related]
29. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
31. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
32. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
35. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
36. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.
Liu S; Cadaneanu RM; Zhang B; Huo L; Lai K; Li X; Galet C; Grogan TR; Elashoff D; Freedland SJ; Rettig M; Aronson WJ; Knudsen BS; Lewis MS; Garraway IP
PLoS One; 2016; 11(10):e0163232. PubMed ID: 27711225
[TBL] [Abstract][Full Text] [Related]
37. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
38. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
[TBL] [Abstract][Full Text] [Related]
39. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
[TBL] [Abstract][Full Text] [Related]
40. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram.
Stokkel M; Zwinderman A; Zwartendijk J; Pauwels E; van Eck-Smit B
Eur J Nucl Med; 1997 Oct; 24(10):1215-20. PubMed ID: 9323261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
